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Abstract 
 
Rationale: Endothelial nitric oxide synthase (eNOS) is a crucial enzyme for 
vascular physiology and its reduced activity during aging leads to increased 
cardio and cerebrovascular disease susceptibility1-4. Caloric restriction, 
which delays aging and increases life-span in all species, doesn’t exert any 
effect in mice lacking eNOS5. Long Living Individuals (LLIs) have a 
favourable genetic profile, characterized by an enrichment of alleles that 
protect from aging and cardiovascular disease6, 7. 
We have recently shown that LLIs of three populations are enriched for the 
minor allele rs2070325 (I229V) of the bactericidal/permeability-increasing 
fold-containing family B member 4 (BPIFB4) and that rs2070325 is part of a 
four SNPs haplotype that codified for a Wild Type (WT) and a longevity-
associated variant (LAV) of BPIFB4, that is able to potentiate eNOS 
activity. This unique ability is correlated with its higher efficiency, as 
compared to WT-BPIFB4, in binding 14-3-3 through a BPIFB4 atypical 
binding site for 14-3-3, which correlates with its level of phosphorylation at 
serine 75, a phosphorylation site for stress kinase PERK. HSP90 
recruitment into the complex is part of the eNOS activation machinery 
triggered by LAV-BPIFB4. Indeed HSP90 is co-immunoprecipitated 
together with BPIFB4 and a specific HSP90 inhibitor blocks LAV-BPIFB4 
potentiation on endothelial function and eNOS activation. 
The data so far reported clearly demonstrate that LAV-BPIFB4 activates 
eNOS function trough 14-3-3 and HSP90 recruitment and, as underlined by 
William Sessa in its editorial, further characterization is needed to define 
how LAV-BPIFB4 transduce upstream signals to eNOS 
 
Objective: To further characterize the molecular signaling regulated by 
LAV-BPIFB4 to modulate vascular function.  
  
Methods and Results: Here we show that eNOS activation by LAV-
BPIFB4 is mediated by Ca2+ mobilization and PKC-alpha activation. In 
LAV-BPIFB4 transfected HEK293 cells, there was an enhancement of ATP-
induced Ca2+ mobilization and PKC-alpha translocation on plasma 
membrane. In vascular reactivity studies, LAV-BPIFB4 failed to potentiate 
eNOS and endothelial function upon PKC-alpha inhibition by Gö6976. 
Moreover, when vessels were exposed to external Ca2+-free conditions, 
LAV-BPIFB4 lost the ability to activate PKC-alpha and eNOS. In these 
conditions, though, and in eNOS knockout vessels, LAV-BPIFB4 still 
potentiated endothelial activity, through mechanisms alternative to eNOS, 
and this function was blunted by the inhibitors of the endothelium-derived 
hyperpolarizing factors (EDHF). Notably, peripheral blood mononuclear 
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cells from subjects carrying the a/a genotype for rs2070325 had a 
significant increase of phosphorylation of PKC-alpha (T497).  
 
Conclusions: We have identified novel molecular determinants of the 
beneficial effects of LAV-BPIFB4 on endothelial function, showing the role 
of Ca2+ mobilization and PKC-alpha in eNOS activation and of EDHF 
activation upon eNOS inhibition. These results highlight the role of LAV-
BPIFB4. 
 
 
Nonstandard Abbreviations and Acronyms 
 
BPIFB4 = bactericidal/permeability-increasing fold-containing-family-B-
member-4 
HSP90 = heat shock protein 90 
LAV = longevity-associated variant 
LLIs = long living individuals 
MNC = mononuclear cells 
PERK = protein kinase R–like endoplasmic reticulum kinase 
NO = nitric oxide 
ACh =acetylcholine  
EDHF= endothelium-derived hyperpolarizing factors 
[Ca2+]i = intracellular calcium 
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1. INTRODUCTION 
 
1.1 Definition of aging 
Aging is a complex process ruled by stimuli of different nature and 
belonging to several field of life. Stochastic events contribute to this 
process by producing casual damages to essential molecules, the external 
environment interfere through the life style (diet and/or caloric restriction), 
while the genetic asset provides a background of intrinsic alterations that 
are protective or detrimental for the onset of aging related pathologies. The 
attention on this latter point increased in the last years, promoting the 
search for genetic variations connected with protective features against 
typical age-related disease like hypertension, diabetes and cancer. 
Therefore, longevity is defined as that phenotype of long-living subjects that 
approach old age under the effects of these several factors. 
 
1.2 The longevity phenotype 
The Birth Cohort Study found that in the United State at the beginning of 
twentieth century life expectancy was 51.5 years for males and 58.3 years 
for females; currently 1 person each 10,000 reach 100 years of age, and 
this prevalence is quickly changing and will probably soon approach 1 
person each 5,0008. It was estimated that the increased ability to reach 100 
years old in industrialized countries over the last 160 years reflects a rise in 
life expectancy — quantified as 3 months per year for females — 
subsequent to improvements in diet and a reduced exposure to infection 
and inflammation9. The improvement of healthy care and the attention to a 
balanced and quality food intake speedup the process towards a diffused 
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longevity. In favor of diet as a modulator of longevity, the Elderly 
Prospective Cohort Study (EPIC) identified a reduced overall mortality 
among the elderly consuming a modified Mediterranean diet in which 
saturated fatty acids were substituted for monounsaturated ones10. 
Centenarians, despite being exposed to the same environmental 
conditions as members of the average population, manage to live much 
longer. Long-living individuals (LLIs), i.e. those that approach 100 years of 
age, are a model of successful aging: most of them have a compression of 
disability and morbidity towards the end of their life and tend not to show 
changes normally observed during aging, such as a decrease in insulin 
sensitivity and in heart rate variability (HRV)11-13. The exceptional longevity 
of LLIs is to some extent genetically driven, as underlined by the familial 
clustering effect for extreme longevity and the reduced mortality of 
centenarians’ siblings compared to those of non-centenarians. Under a 
genetic point of view, the compression in morbidity and mortality is 
correlated with the enrichment of protective alleles and the depletion of 
detrimental ones. It has been estimated that genetic variants account for at 
least 25% of human life-span, and for even a larger proportion in 
individuals living to extreme age6, 14. 
Ultimately, aging is an independent risk factor associated with endothelial 
dysfunction, impaired angiogenesis and loss of protein homeostasis, or 
proteostasis, the decline of which is contrasted by adaptive cellular 
responses15. The mechanisms that help cells adapt and survive under 
stressful conditions include the activation of heat shock factor protein 1 
(HSF1)-controlled heat shock proteins (HSPs), ribosomal biogenesis and 
protein synthesis, and are at least in part orchestrated by growth factors, 
as observed in Caenorhabditis elegans, in which HSF-1 is under the 
control of insulin/IGF-1-like signaling (IIS)16. 
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1.3 Genome-Wide Association Studies 
In our studies on longevity phenotype, we follow the genetic trait by trying 
to characterize the functional aspects of the genetic background that make 
a person a centenarian. Genome Wide Association Studies (GWASs), that 
analyze the differences in the frequencies of presence of common genetic 
variants in two populations - cases and controls - generate findings that 
need to be replicated in independent populations. In the case of 
exceptional longevity, success in replicating initial findings is negatively 
influenced by the differences in participant ages, gender and disease 
status distribution across the analyzed populations. Furthermore, the 
GWAS approach suffers from the multiple-testing statistical penalty that 
forces the adoption of very low p-values of significance, hence favouring 
the phenomenon of the winning course, i.e. the enrichment of false-positive 
associations among the dozens of top findings17. Other potential problems 
that generate false positive and false negative results include the low 
power of studies using small sample sizes, and a lack of a suitable control 
for the genetic admixture. On the first point, an extremely instructive review 
has been written by Altshuler, Daly and Lender, who calculate the power of 
a study based on the number of individuals genotyped, the number of 
tested hypotheses, and the frequency of the allele tested for a specific 
OR18. From the graph given in their review (Figure 1.1), it is clear that for 
the OR expected in human exceptional longevity (between 1.2 and 2), the 
power of a study is highly dependent upon the number of hypotheses 
tested.  
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Figure 1.1 Sample sizes required for genetic association studies.  
The graph shows the total number N of samples (consisting of N/2 cases 
and N/2 controls) required to map a genetic variant as a function of the 
increased risk due to the disease-causing allele (x axis) and the frequency 
of the disease-causing allele (various curves). The required sample size is 
shown in the table on the right for various different kinds of association 
studies18. Reproduced with permission from The American Association for 
the Advancement of Science. 
 
For these reasons, recent GWASs have failed to find variants that cross-
validate across populations — with the exception of few cases — pointing 
to the need of much larger studies or alternative study designs in order to 
discover common polymorphisms with smaller genetic effects and rare 
variants with high penetrance that influence exceptional longevity19, 20. 
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Thus, a GWAS on exceptional longevity can be considered only a 
hypothesis-generating effort to be used in conjunction with other studies. 
 
To date, the most remarkable genetic findings for exceptional longevity 
observed in the genome of centenarians are the decreased frequency of 
detrimental alleles of apolipoprotein E (APOE) and the increase of 
protective alleles of forkhead box O3A (FOXO3A)21-26. 
Recently, we found associated with longevity three more variants in 
CAMKIV, ATXN1 and DCAMKL1 (Table 1.1)27. 
APOE is involved in lipid transport to the lymph system and was the first 
gene to be successfully replicated as a gene important in exceptional 
longevity28. FOXO3A mediates a pro-survival activity by regulating the 
cellular response to stimuli ranging from radical stress to growth factors 
[Insulin growth factor 1 (IGF1)], and by acting on the transcription of genes 
involved in radical stress response, cell cycle arrest, proliferation, and 
apoptosis29, 30. Protein Kinase B (AKT)-dependent phosphorylation and 
sirtuin 1 (SIRT1)-dependent deacetylation of FOXO3A induce pro-survival 
activity by activating genes linked to the stress response and cell cycle 
arrest and by inhibiting pro-apoptotic genes31. In humans, genetic 
alterations of the IGF1 receptor that alter the IGF signaling pathway confer 
an increase in propensity for longevity32. AKT polymorphisms have also 
been associated with human longevity26. 
 
Table 1.1 Genes and variants found correlated with longevity in 
humans 
Gene Variant Occurrence 
in 
centenarians 
Previous 
disease 
correlations 
Potential 
role in 
longevity 
APOE 4 reduced Alzheimer’s Maintenance 
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and 
cardiovascular 
diseases 
of vascular 
integrity 
FOXO3A rs2802292* more present none Control of cell 
homeostasis 
CAMK4 rs10491334† more present hypertension Modulation of 
CREB, SIRT 
and FOXO3A 
ATXN1 rs697739 more present amyotrophic 
lateral 
sclerosis (age 
of onset) 
Modulation of 
CREB 
DCAMKL1 rs9315385 more present heart rate 
variability 
Modulation of 
CREB 
*, result obtained by a candidate gene approach and replicated in other 
studies; †, result obtained from a GWAS and confirmed in a replication 
cohort. 
 
For the above reasons, in our recently published GWAS on individuals 
enrolled in the Southern Italian Centenarian Study (SICS), we identified 
CAMK4 rs10491334, a variant that had been already established among 
the top 5 SNPs in the Framingham Heart Study on diastolic high blood 
pressure33. The fact that CAMK4 rs10491334 associates also with 
hypertension is reassuring in that hypertension and longevity are regulated 
by common pathways. In fact, mice with genetic ablation of the angiotensin 
II type1 receptor — the key regulator of blood pressure — had increased 
expression of the longevity gene Sirt3 and improved survival34. 
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Interestingly, rs10491334 correlated with CAMK4 protein expression, and 
functional studies revealed the ability of CAMK4 protein to modulate SIRT1 
and FOXO3A (Figure 1.2). 
 
 
Figure 1.2 Western blot analysis of calcium/calmodulin-dependent 
protein kinase IV (CAMKIV). 
(A) Western blot analysis of CAMKIV revealing higher CAMKIV levels in 
mononuclear cells of subjects expressing wild-type CAMKIV (CAMKIV WT) 
compared to subjects homozygous for the CAMKIV minor allele (CAMKIV 
rs10491334). CAMKIV levels were normalized to actin (corrected 
densitometry units, CDU; n=10). (B and C) Western blot analyses of HT29 
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cells expressing CAMKIV revealing a significant increase of 
phosphorylated FOXO3A, AKT, and SIRT1 compared with cells infected 
with empty vector (MOCK). Data from immunoblots were quantified by 
densitometric analysis. Statistics were performed with analysis of variance 
(ANOVA). (*) p<0.05; (**) p<0.005; (***) p<0.0005. 
 
  
The ataxin-1 (ATXN1) rs697739 allele was another variant found among 
the top findings of our GWAS on SICS individuals. This polymorphism had 
been previously associated with the age of onset of sporadic amyotrophic 
lateral sclerosis, a disease of unknown cause characterized by slowly 
progressive degeneration of motor neurons and that usually occurs in 
patients aged 40–60 years35. ATXN1 is the gene responsible for 
spinocerebellar ataxia type 1 andantagonizes the neuronal survival 
function of myocyte enhancer factor-2 (MEF2)36. MEF2 transcription 
repression by cabin1-HDAC4 is removed by CAMKIV activation, and this 
suggests that MEF2 is a common downstream target of CAMKIV and 
ATXN137, 38. 
In addition to CAMKIV rs10491334 and ATXN1 rs697739, the rs9315385 
allele of doublecortin and Ca2+/calmodulin-dependent kinase-like-1 
(DCAMKL1) was a third top finding of our study. DCAMKL1 has structural 
similarity with CAMKIV, but despite this, it represses CAMKIV-induced 
activation of cAMP response element-binding (CREB) protein via 
phosphorylation of transducer of regulated CREB activity 2 (TORC2) at 
Ser17139. DCAMKL1 rs9315385 was previously associated with total 
power of HRV40. A reduced HRV is a marker of autonomic dysfunction and 
is associated with an increased risk of cardiovascular morbidity and 
mortality41. HRV-parasympathetic function decreases up to the eighth 
decade of life, followed by an increase to higher levels — similar to those 
found in a younger population — in nonagenarians and centenarians13. 
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Similarly to CAMKIV, DCAMKL1 and ATXN1 are expressed mainly in 
brain. These data support the importance of the CAMKIV/CREB pathway 
in regulating the aging process. 
A brief mention needs to be made here on the cutting edge, genetic 
signature paper by Sebastiani et al. that very elegantly proved that a 
complex analysis on 281 SNPs allowed to define clusters of individuals 
that aged differently based on their genetic signature42. 
The identification and the study of genetic variants that influence 
exceptional longevity in humans are important, since novel targets for 
prevention and therapy of a large spectrum of age-related diseases could 
be discovered43. Genome-wide association studies (GWAS) are 
hypothesis-generating studies that can be used to this end.  
 
1.4 Aging process theories 
1.4.1 Free radicals theory 
One of the theory that tempts to explain the aging process is the free 
radicals theory. Responsible for oxidative stress, free radicals are 
defined as atoms or molecules that contain one or more unpaired 
electrons. Biological systems depend on these kind of molecules: the 
most important are the reactive oxygen species (ROS) superoxide 
anion radical (O2
.), hydrogen peroxide (H2O2), alkoxyl (RO
.), peroxyl 
(ROO.) and hydroxyl (.OH) radicals, and hypochlorous acid (HOCl)44. 
In 1956 Denham Harman proposed the “free-radical theory of aging” 
(FRTA)45 that postulated that accumulation of free radicals was the 
prime cause of the sequential alterations characterizing advancing age 
and the progressive increase in disease and death rates46. This 
hypothesis was based on the “rate of living” theory formulated by 
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Raymond Pearl explaining longevity variation within species in terms of 
combined mass-specific resting metabolic rate and the “lifetime energy 
potential”: it held that the pace of life is inversely related to the length 
of life47. 
In the oxygen managing system of the cell, mitochondria play an 
important role and physiological or pathological dysfunctions of them 
are associated with aging or age-related diseases48. The aging 
process, indeed, is associated with the improvement of the 
mitochondrial production of ROS, specially in heart and in the 
vasculature system. In the heart, the last evidences are cardiac 
hypertrophy, fibrosis and apoptosis. In the vasculature system the 
mitochondrial oxidative stress and the presence of ROS contribute to 
the development of chronic low-grade vascular inflammation in aging49 
by activating redox signaling pathways. In addition, the ROS activation 
of Akt pathway increases the development of the senescent phenotype 
in endothelial cells characterized by an impairment in the ability of 
regeneration and angiogenesis, and a general reduction in vascular 
reactivity and increasing in atherosclerosis events due to less 
cytokines vessel production50. 
A proved way to overcome to the rapid aging of mitochondria and 
consequently of cardiovascular system, is exercise. It’s clear that the 
physical activity brings to a stress–induced NO production able to 
restore vascular activity and endothelial cells protein homeostasis51. A 
similar effect is achieved by a caloric restriction lifestyle or by the 
administration of caloric restriction mimetics, in which the energy 
sensor AMPK upregulates SIRT activity restoring the vessels activity. 
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1.4.2 Lipid metabolism and aging 
In apparent contrast with the FRTA is the finding that the cell 
membranes of offspring of nonagenarians have an accumulated 
amount of endogenous trans fatty acids52. The peroxidation index of 
erythrocyte membrane lipids was significantly lower in nonagenarians’ 
offspring than in a group of matched controls52. It is of particular interest 
that we found significantly increased levels of palmitoleic acid (C16:1n-
7) in the nonagenarians’ offspring, similarly to what was later observed 
in genetically modified long-living worms53. Because these worms were 
genetically modified in homologue genes of the insulin-like growth 
factor 1 (IGF1)/forkhead box O3 (FOXO3A) axis, a possible 
explanation for this finding is that IGF-1 signalling modulates, or is 
modulated by, the membrane fatty-acid composition54. Moreover, it was 
reported that after chronic thermal or saline stress of yeast, the induced 
increase in the level of membrane palmitoleic acid was responsible for 
a reset of heat shock protein (Hsp) release to higher levels55. Thus, the 
high C16:1n-7 detected in the offspring of nonagenarians could be 
correlated to the low serum level of Hsp70 detected in centenarians’ 
offspring56. Endogenous trans fatty acids are an index of endogenous 
free-radical cellular stress and are produced by endothelial nitric oxide 
synthase (eNOS)-generated nitrates (NO2·), as shown by the lack of 
trans-arachidonic acids in the retinas of eNOS-/- mice57. Moreover, 
calorie restriction, which is known to increase longevity, induces the 
expression of eNOS, the activation of telomerase and the biogenesis of 
mitochondria. Thus, the increase in ROS observed with calorie 
restriction suggests a role for free-radical stress: the induction of 
endogenous defense mechanisms, maybe through trans fatty acids 
participation, that culminate in increased resistance to stress and 
longevity. This adaptive response was named hormesis58. From this 
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point of view, the FRTA formulated by Harman doesn’t appear 
consistent and these findings, taken together, suggest that ROS can 
act as essential signaling molecules for the promotion of metabolic 
health and longevity.  
The degree of oxidative stress could possibly explain this apparent 
paradox: a low stress situation results protective for organism, while 
massive stress becomes deleterious. In support of this hypothesis, 
deletion in worms of mitochondrial proteins, such as ISP-1 and NUO-6, 
induces the oxidative stress necessary and sufficient for promoting 
longevity: in fact, this effect is abolished by antioxidants and is induced 
by mild treatment with oxidants (Figure 1.3)59.  
 
 
Figure 1.3 Schematic of vascular physiological function 
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1.5 Nitric Oxide and its prevalent role in the vascular 
system 
The beneficial effects of calorie restriction are multiple: it reduces the 
incidence of tumors and diabetes and the age-related decline in T-
lymphocyte proliferation60. The effects of calorie restriction can be 
explained by increased IGF1-insulin signal (IIS) efficiency: in fact, findings 
on patients with growth hormone receptor deficiency suggest that their high 
insulin sensitivity could account for the absence of diabetes and very low 
incidence of cancer seen in these individuals61. Furthermore, calorie 
restriction can be mimicked by genetic manipulation aimed at blocking IIS 
(i.e., the IGF1/PI3K/AKT/FOXO3A axis): for example, the FIRKO mouse − 
a carrier of a fat-specific insulin receptor knockout − and C. elegans models 
carrying null mutations of daf-2 − an IGF1 homologue − and age-1 − a 
homologue of the catalytic subunit of mammalian PI3K− all live longer than 
wild-type animals62, 63. To be noted, the beneficial effects of daf-2 and age-1 
null mutations are antagonized by null mutation of daf-16, which encoder 
three members of the FOXO family of transcription factors63. Thus, via AKT 
the IIS is important for controlling eNOS and, hence, human longevity64. 
Exercise is inversely correlated with total mortality65. An elegant report on 
athletes undergoing marathon training identified a combination of 
metabolites (i.e., glycerol, niacinamide, glucose-6-phosphate, pantothenate 
and succinate) that increased in the plasma in response to exercise; in 
vitro, these metabolites were able to up-regulate the expression of NUR77, 
a transcriptional regulator of glucose utilization and lipid metabolism 
genes66. NUR77 is under the control of Ca2+/calmodulin-dependent protein 
kinase (CAMKIV), which is activated by AMPK and has been associated 
with human exceptional longevity27, 38. Furthermore, AMPK controls eNOS 
phosphorylation, which explains the potentiation of eNOS activity by both 
calorie restriction and physical exercise.64 AMPK is activated acutely at 
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exercise intensities above ≈ 60% of maximal aerobic capacity67. Calorie 
restriction and exercise both activate mitochondrial biogenesis through 
activation of AMPK with an eNOS-dependent mechanism, as shown by 
experiments on eNOS knockout mice68. Thus, the beneficial effects on 
longevity of calorie restriction, genetic makeup and exercise can be 
explained, at least in part, through eNOS-dependent activation of 
mitochondrial biogenesis. 
During the aging process, oxidative stress increases in the arterial system 
either of humans and experimental models69. This phenomenon has been 
linked directly to the development of atherosclerotic vascular diseases 
(Figure 1.4).  
We think that the state of the vascular system is the most important factor 
in determining health during aging. In fact, vascular system is responsible 
for the transport of oxygen and nutrients throughout the body and, 
therefore, is responsible of when and how the organs and systems could 
encounter suffering and ultimately fail. In the end, oxidative-stress-induced 
endothelial dysfunction is probably the key mechanism linking older age to 
increased risk of clinical cardiovascular disease and death70. 
Free radicals play a physiological role in the vessel wall as well: they 
participate as second messengers in endothelium-dependent functions, in 
smooth muscle cell and endothelial cell growth and survival, and in 
remodeling of the vessel wall71. When these processes are out of control, 
they contribute to vascular alterations characterized by mitochondrial 
dysfunction and increased ROS production,72 and lead, ultimately, to the 
development of cardiovascular pathologies, such as hypertension, stroke 
and coronary artery disease.73, 74. 
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Figure 1.4 a) Representative nitric oxide pathway. b) Effects of aging 
on nitric oxide pathway. 
BH4 = tetrahydrobiopterin; cGMP = cyclic guanosine monophosphate; GTP 
= guanosine triphosphate; NADPH = nicotinamide adenine dinucleotide 
phosphate; ONOO- = Peroxynitrite; ADMA = Dimethylarginine 
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One of the most important mediators in the cardiovascular system is nitric 
oxide (NO). During aging, increased oxidative stress leads to a progressive 
decrease in NO production. In particular, this is caused by eNOS 
uncoupling − a phenomenon that promotes the formation of superoxide 
rather than NO − and decreased expression of the essential eNOS cofactor 
tetrahydrobiopterin (BH4)3. In fact, superoxide produced mainly by NADPH 
oxidase may react with NO to produce peroxynitrite that, promoting eNOS 
uncoupling, contribute to the increase of superoxide and to the reduction of 
NO that may cause an acceleration of the atherosclerotic process75. Thus, 
abnormalities in eNOS signalling underlie endothelial dysfunction, a 
common finding in aging. 
Several studies emphasize the importance of mitochondrial oxidative 
stress, which represents a typical characteristic of endothelial dysfunction 
that develops during aging and it is associated with the over-activation of 
an important enzyme, which is localized both in the cytoplasm that in 
membrane, namely NADPH oxidase76, 77. 
Deshpande et al. demonstrated that Rac1 − a regulatory component of 
plasma membrane NAD(P)H oxidases − plays an important role in 
premature aging of the endothelium and in the development of associated 
vascular pathologies78, 79. In addition, other molecular mechanisms 
responsible for age-related mitochondrial oxidative stress in the vasculature 
involve dysregulation of antioxidant defences, such as peroxynitrite-
mediated Nrf2/ARE (antioxidant response elements) dysfunction , nitration 
and inhibition of manganese superoxide dismutase (MnSOD), declines in 
glutathione (GSH) content and a dysfunctional electron transport chain69. 
Nrf2 is a redox-sensitive transcription factor that upregulates the expression 
of numerous ARE genes that encode proteins that detoxify ROS and 
mediate the anti-aging effects of calorie restriction80. Recent findings 
demonstrate that Nrf2 dysfunction in the vasculature is associated with 
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aging and contributes to the age-related dysregulation of GSH synthesis in 
various tissues. 
Van der Loo et al. provided evidence for association between the formation 
of peroxynitrite and age-associated vascular dysfunction by demonstrating 
selective nitration of MnSOD − the major antioxidant enzyme in the 
mitochondria of all mammals − with increased age81. This finding was 
supported by a recent report showing that genetic inactivation of MnSOD in 
mutant mice resulted in premature death and that treatment with a SOD 
mimic dramatically prolonged survival. 
Moreover, the activities of various electron transport chain oxido-
reductases are deleteriously affected during aging. The mitochondria 
generate ATP from nutrients, and its synthesis via the mitochondrial 
respiratory chain is the result of a proton potential generated by the 
electron transport chain. Damage to this latter can cause breakdown of the 
proton potential, apoptosis and the generation of free radicals in a vicious 
cycle82. 
According to the FRTA, ROS are the major candidates responsible for 
senescence and age-related diseases in which the redox balance is 
disturbed and generates oxidative stress. Indeed, senescence of 
endothelial cells has been proposed to be responsible for endothelial 
dysfunction and atherogenesis during aging. In fact, vascular cells 
exhibiting the morphological features of cellular senescence have been 
found in atherosclerotic lesions83. 
 
Relatively recent studies have demonstrated that inhibition of Sirt1 induces 
premature senescence and that Sirt1 overexpression reverts premature 
senescence induced by hydrogen peroxide. In macrophages in vitro and in 
rats in vivo, Sirt1 inhibits NF-kB and so hinders pro-inflammatory mediator 
release, protecting from the development of oxidative stress84. 
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Finally, there are several findings that relate telomere shortening to aging 
in vivo. Telomeres are regions of DNA, characterized by G-rich sequences 
located at the ends of linear chromosomes that can form four-stranded 
structures: they are considered a biological clock that measures mitotic 
time and determines the senescence of cell replication. There appears to 
be a correlation between telomere length, age and oxidative stress in 
human arteries at sites of elevated hemodynamic stress and, presumably, 
with a high cell turnover. Data suggest that G-rich strands are more 
vulnerable to oxidative damage and that faster telomere shortening rates 
are observed in cell strains that also have higher peroxide levels. Thus, 
telomere loss is clearly implicated in oxidative damage, accumulation of 
senescent cells in elderly individuals and reduction in lifespan85 (Figure 
1.5). 
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Figure 1.5 Schematic of the involvement of free radicals in vascular 
ageing. 
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1.6 Longevity populations 
We recruited and genotyped 582 LLIs (age range 90-109 years) and 784 
young control individuals (age range 18-45 years) as part of the Southern 
Italian Centenarian study (SICS). SICS LLIs were thoroughly investigated 
for demographic characteristics, medical history (past and present 
diseases), level of independence (Barthel Score)86,and cognitive status 
(Cognitive Score) (Table 1.2). 
 
Table 1.2 Characteristics of SICS screening-set (N=410) and SICS 
replication-set LLIs (N=116) 
 
 
SICS LLIs - Screening 
(N=410) 
SICS LLIs - Replication 
(N=116) 
Variable/Diseas
e N % 
Me
an SD 
Mi
n 
Ma
x N % 
Me
an SD 
Mi
n 
Ma
x 
Demographics             
 Gender (Males) 
24
0 
58.
82     
5
4 
46.
96     
 Age   
96.
62 
3.6
4 90 
10
9   
96.
14 
3.5
2 90 
10
9 
Patient’s History             
 Deceased, Age 
at Death 
31
3 
76.
72 
96.
95 
3.5
9 90 
10
9 
8
7 
75.
65 
96.
08 
3.3
2 90 
10
9 
 Smoking 
History 97 
23.
77     
3
0 
26.
09     
 Diabetes 
Mellitus 36 
8.8
2 
79.
74 
11.
69 54 94 
1
9 
16.
52 
73.
18 
12.
12 50 91 
 Overweight 
(BMI >25) a 74 
25.
00     
2
3 
24.
73     
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 Osteoporosis 34 
8.3
3 
74.
92 
12.
96 50 91 8 
6.9
6 
77.
25 
15.
39 55 90 
 Heart Attack 32 
7.8
4 
83.
07 
11.
39 50 97 
1
1 
9.5
7 
81.
73 
10.
55 60 93 
 Cardiac 
Arrythmia 81 
19.
85 
86.
09 
9.5
1 50 
10
2 
2
1 
18.
26 
80.
35 
16.
8 20 96 
 Angina 7 
1.7
2 
76.
4 
12.
03 60 92 1 
0.8
7 80 NA 80 80 
 Congestive 
Heart 17 
4.1
7 
81.
77 
10.
25 70 97 6 
5.2
2 86 
7.2
1 77 95 
 High Blood 
Pressure 
12
4 
30.
39 
79.
47 
11.
27 38 
10
4 
5
7 
49.
57 
74.
31 
14.
58 20 96 
 Stroke 38 
9.3
1 
87.
35 
7.3
2 70 98 
1
3 
11.
3 
85.
69 
7.4
9 69 93 
 Kidney Disease 18 
4.4
1 
81.
06 
16.
42 27 93 3 
2.6
1 
93.
33 
4.1
6 90 98 
 PVD Circulatory 
Problems 34 
8.3
3 
85.
97 
7.0
7 70 
10
0 
1
2 
10.
43 
80.
75 
14.
85 40 96 
 Cataracts 
14
8 
36.
27 
84.
01 
9.3
6 40 
10
0 
4
6 40 
84.
3 
8.0
3 65 98 
 Glaucoma 13 
3.1
9 
86.
11 
8.3
3 66 93 6 
5.2
2 94 NA 94 94 
 Macular 
Degeneration 10 
2.4
5 85 
7.7
8 77 93 9 
7.8
3 
78.
33 
3.5
1 75 82 
 Thyroid 
Condition 5 
1.2
3 
55.
6 
15.
44 31 68 3 
2.6
1 
75.
5 
20.
51 61 90 
 
SICS LLIs - Screening 
(N=410) 
SICS LLIs - Replication 
(N=116) 
Variable/Diseas N % Me SD Mi Ma N % Me SD Mi Ma
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e an n x an n x 
 
Emphysema/Bro
nchitis 89 
21.
81 
74.
92 
15.
81 35 
10
2 
2
6 
22.
61 
76.
21 
14.
81 50 94 
 Other Illnesses 34 
8.3
3 
75.
5 
25.
54 10 
10
3 
1
0 8.7 
67.
29 
29.
49 15 90 
 Cancer 27 
6.6
2 
80.
88 
13.
25 48 95 5 
4.3
5 
80.
2 
4.2
1 73 83 
 Parkinson’s 
Disease 13 
3.1
9 
85.
08 
8.2
4 65 95 4 
3.4
8 
79.
67 
1.5
3 78 81 
 Dementia 15 
3.6
8 86 
5.6
6 78 94 2 
1.7
4 90 NA 90 90 
 Depression 15 
3.6
8 
85.
23 
3.3
5 80 90 1 
0.8
7 94 NA 94 94 
 Anxiety 13 
3.1
9 
85.
82 
11.
92 60 98 3 
2.6
1 
81.
33 
14.
01 70 97 
Independence 
and Cognitive 
Score             
 Barthel Score c   
65.
93 
37.
66 0 
10
0   
69.
52 
37.
14 0 
10
0 
 Cognitive Score 
c   
28.
85 
10.
33 0 34   
27.
65 
11.
79 0 34 
Abbreviations: Variable/Disease, analyzed variable/disease; N = number of 
LLIs affected/carrying the disease/trait;  %, percentage of LLIs carrying the 
disease/trait; Mean, SD, Min, Max: mean, standard deviation, minimum, 
maximum of the age at onset for each disease.  
a Overweight condition: Body Mass Index (BMI) > 25. BMI has been 
calculated as Weight (kg) / (height (m) x height (m))  
b Peripheral Vascular Disease Circulatory Problems 
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c Mean, standard deviation, minimum, maximum of the Barthel and 
Cognitive Scores distribution are reported instead of mean, standard 
deviation, minimum, maximum of the age at onset. 
 
The control populations were constituted by a German and a US cohort. 
The German sample comprised 1,628 LLIs (age range, 95–110 years; 
mean age, 98.8 years) and 1,104 younger controls (age range, 60–75 
years old; mean age, 66.8 years), and was first described by Nebel et al20. 
The study protocol was approved by the Ethics Committee of University 
Hospital Schleswig–Holstein (Campus Kiel), Germany, and local data 
protection authorities. The US-American study sample consisted of 1,461 
LLIs with an age range of 91–119 years (mean age, 100.8 years) and 526 
controls with an age range of 0–35 years (mean age, 28.2 years); these 
individuals were recruited by Elixir Pharmaceuticals, either directly or 
through the New England Centenarian Study87, 88.The study protocol was 
approved by the Boston Medical Center’s Institutional Review Board and by 
the Western Institutional Review Board. 
 
 
1.7 Genotype determination and statistical data 
interpretation 
Genotyping was carried out using the Illumina BeadChip 317K. All 
genotypes were evaluated using a quantitative quality score called GenCall 
that assigns a score values from 0 to 1 and reflects the proximity within a 
cluster plot of the intensities of that genotype to the centroid of the nearest 
cluster. Samples and SNPs showing Call Rate lower than respectively 93% 
and 95 % as well as SNPs deviating from Hardy Weinberg Equilibrium 
(HWE) (p < 1.72x10-7) or with Minor Allele Frequency (MAF) lower than 
0.05 were removed. Principal Component Analysis (PCA) has been 
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applied on a reduced set of autosomal markers showing r2 estimates < 0.2, 
using the default outliers removal threshold (sigma=6) as implemented in 
Eigenstrat89. We looked for evidence of genetic population stratification on 
a subset of 454 LLIs and 591 young controls by applying PCA: a graphical 
inspection of the first two principal components revealed genetic 
homogeneity between LLIs and controls (Figure 1.3). 
 
Figure 1.3 Population structure  
Population structure of long-living individuals (LLIs) (+) and control subjects 
(∆). Each scatter plot shows the first two principal components that were 
estimated using genotype data for Southern Italian Centenarian Study 
(SICS) LLIs and control subjects using the EigenSoft program. The two 
populations are ethnically identical, as shown in the right scatter plot. 
 
 
 
 
1.8 rs2070325 in BPIFB4 associates with exceptional 
longevity in three independent populations 
In order to follow up our previous hypothesis-generating genome-wide 
association study, we designed a two-stage replication effort on four 
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variations reported among the top findings (P<1x10-4) of that study. To this 
end, two non-synonymous SNPs — i.e., rs2070325 and rs571391 — and 
two intronic markers — i.e., rs7583529 and rs285097, which tagged the 
functional variants rs7917 and rs16955011 (r2>0.8 in the HapMap CEU 
panel), respectively — were tested for association in two independent 
cohorts, the first of which was recruited for the German Longevity Study,20 
and the second for a US-based effort.  
Of the four variations tested with TaqMan assays, only rs2070325 — which 
induces the amino acid change Ile229Val in BPIFB4 (identifier: P59827-2) 
— replicated the association observed in the screening cohort under the 
recessive genetic model (OR = 2.42; 95% CI = 1.56–3.77; P = 5.8 x 10-5; 
power >0.85) in the German Longevity Study (OR = 1.43; 95% CI = 1.12–
1.80; P = 0.0036). This variant resulted associated with the longevity 
phenotype also in the USA replication set (OR = 1.60; 95% CI = 1.14–2.24; 
P = 0.0063). Meta-analysis of the two populations confirmed this finding 
(3,060 LLIs and 1,609 controls: OR = 1.49; 95% CI = 1.22–1.81; P= 7.59 x 
10-5; power >0.90) and that of the screening and replication sets combined 
(3,464 LLIs and 2,160 controls; Bonferroni-adjusted significance threshold: 
P<3.22 x 10–7; OR = 1.61; 95% CI = 1.34-1.92; P= 2.4 x 10–7; power >0.80)  
 
1.9 rs2070325 is associated with a quadruple-SNP 
haplotype 
Haplotype analysis revealed patterns of strong linkage disequilibrium (LD: 
r2>0.8, D′>0.9) within the BPIFB4 genomic locus, delimiting a region highly 
enriched in non-synonymous SNPs: the rs2070325 variation of BPIFB4 
tagged rs2889732 (Asn281Thr), rs11699009 (Leu488Phe) and rs11696307 
(Ile494Thr), codifying respectively for wild-type (WT) (allele frequency, 
66%) and longevity-associated variant (LAV) (allele frequency, 29.5%) 
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isoforms. 
BPIFB4 belongs to the superfamily of bactericidal BPI/PLUNC proteins, 
which are central to the host innate immune response against bacteria in 
regions of significant bacterial exposure, like the mouth, nose and lungs. 
The expression of the activity-enhanced polymorphic variant LAV-BPIFB4 
might initially produce privileged survival through better resistance to 
infectious diseases. 
 
1.10 BPIFB4 overexpression induces an adaptive 
stress response and proteostasis 
In order to gain information on the role of BPIFB4 and its LAV in gene 
expression regulation, we performed genome-wide transcriptional profiling 
of HEK293T cells transfected with an empty-, WT- or LAV-BPIFB4-
encoding vector. BPIFB4 isoforms activated adaptive stress responses and 
proteostasis, two key aspects for improved organism survival5 and stem cell 
maintenance,90 and potentiated small noncoding RNAs supportive of the 
spliceosome, genomic integrity machinery and telomere maintenance, 
indicative of a role of the protein in organism homeostasis  
 
1.11 PERK modulates the complexing of LAV-BPIFB4 
with 14-3-3  
To further dissect the molecular determinants underlying the mechanism of 
action of BPIFB4, we analyzed the structure of the protein motifs in its 
sequence. We identified a protein kinase R (PKR)-like endoplasmic 
reticulum kinase (PERK) substrate motif (amino acids 73–80: 
EXSXRXXR/EGSIRDLR)91, 92. PERK is a known transducer of the unfolded 
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protein response, reducing endoplasmic reticulum (ER) protein loading 
through the inhibition of protein synthesis mediated by phosphorylation of 
eukaryotic translation initiation factor 2 (eIF2)-alpha93; thus, a PERK 
substrate motif on BPIFB4 would indicate a role of BPIFB4 as a 
downstream effector. Specifically, we observed a reduction of eIF2-alpha 
phosphorylation upon transfection with BPIFB4. These findings suggest 
that BPIFB4 is part of a cascade of events orchestrated by PERK aimed at 
reducing ER stress94. 
Further sequence analysis revealed the presence also of an atypical 14-3-3 
binding motif (amino acids 80–86: RXSXXXS/RNSGYRS)95. 14-3-3 
modulates cell signaling by binding and/or retaining proteins within the 
cytoplasm based on their phosphorylation status96. 
We next compared LAV-BPIFB4 and WT-BPIFB4 for potential interaction 
with 14-3-3 in vitro. Immunoprecipitation and confocal analyses revealed 
that LAV-BPIFB4 was mainly localized in the cytoplasm and efficiently 
formed a complex with 14-3-3, whereas WT-BPIFB4 was mostly nuclear. 
Cells transfected with LAV-BPIFB4 mutated either at serine 75 (LAV-
BPIFB4mutPERK) or at serine 82 (LAV-BPIFB4mut14-3-3), which is part of the 14-
3-3 binding motif, failed to immunoprecipitate 14-3-3, indicating a role of 
these sites in 14-3-3 recruitment. 
Further characterization of LAV-BPIFB4 interactions revealed that it forms a 
complex with heat shock protein 90 (HSP90), a phenomenon that does not 
take place in cells transfected with LAV-BPIFB4mutPERK or LAV-BPIFB4mut14-
3-3. Pharmacological inhibition of PERK with GSK2606414 after transfection 
with LAV-BPIFB4 impeded the immunoprecipitation of 14-3-3 and HSP90. 
These findings link PERK-mediated phosphorylation of LAV-BPIFB4 to its 
14-3-3 binding activity, which is central for the recruitment of HSP90, a 
known eNOS activator97. 
Of note, WT-BPIFB4 co-immunoprecipitated with HSP90, but not with 14-3-
3, as detected by Western blotting. However, WT-BPIFB4mut14-3-3 failed to 
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immunoprecipitate with HSP90. This indicates that WT-BPIFB4 has a 
reduced, rather than no, ability to recruit 14-3-3, which is a step needed for 
forming a complex with HSP90. 
 
1.12 eNOS is phosphorylated in homozygotic 
rs2070325 MNCs 
Aging is generally associated with a significant reduction in NO 
bioavailability, which leads to endothelial dysfunction3. Based on the 
previous observations of HSP90 recruitment by BPIFB4, we assessed the 
effect of the A/A (homozygotic major allele), A/a (heterozygotic allele) and 
a/a (homozygotic minor allele) genotypes of rs2070325 on the activity 
status of eNOS in MNCs from healthy blood donors. We found increased 
eNOS phosphorylation at serine 1177 — an activation site of the enzyme 
— in a/a carriers94. 
 
1.13 BPIFB4 is present in the vessel wall and 
modulates vascular tone 
Based on the evidence of enhanced eNOS phosphorylation in MNCs with 
an rs2070325 genotype, we explored the role of BPIFB4 in the modulation 
of vascular tone, a process in which NO plays a prominent role3. In mouse 
mesenteric arteries — a typical resistance vessel involved in blood 
pressure homeostasis — expression of the protein was upregulated upon 
application of a biomechanical stress (i.e., increased intraluminal pressure) 
(Figure 1.13A). Inhibition of BPIFB4 expression had a detrimental effect on 
vascular function: indeed, siRNA-mediated knockdown of BPIFB4 induced 
marked reductions in phenylephrine- and potassium-evoked 
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vasoconstrictions (Figure 1.13B); in addition, acetylcholine-evoked 
endothelial vasorelaxation was impaired, clearly indicating endothelial 
dysfunction (Figure 1.13B). These effects were associated with the 
inhibition of eNOS phosphorylation at serine 1177 (Figure 1.13C). These 
findings on eNOS phosphorylation status and vascular tone modulation by 
BPIFB4 could be related to the role of BPIFB4 in recruiting 14-3-3/HSP90 
and facilitating eNOS phosphorylation. So we next investigated the impact 
of BPIFB4 variants at the vascular level. 
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Figure 1.13.  Expression of BPIFB4 in perfused vessels and effects of 
its variants on vascular reactivity and on phosphorylation of eNOS 
and PKC-alpha in mesenteric arteries. A, BPIFB4 protein expression in 
ex vivo mouse mesenteric arteries perfused with increasing pressure 
levels. The right graph gives quantification of BPIFB4 protein. B, The 
graphs show, from left to right, the vascular response of ex vivo mouse 
mesenteric arteries to potassium (80mM KCl), and the dose–responses to 
phenylephrine (PE), to the thromboxane agonist U46619, and to 
acetylcholine (ACh). In the first row, the vascular responses are measured 
before ( - ) and after (  + ) transfection with short interfering (si)RNA for 
BPIFB4, and before (  - ) and after (  + ) transfection with scrambled 
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siRNA. In the consecutive rows, before ( - ) and after (  + ) transfection 
with an empty (E) plasmid, or with wild-type (WT) or the longevity 
associated variant (LAV) BPIFB4-encoding plasmids. Values are means ± 
SEM. N=7 experiments per group. Statistics was performed using ANOVA; 
***, p<0.001, before vs after transfections. C, Western blot of seven pooled 
experiments on ex vivo mouse mesenteric arteries transfected with a 
BPIFB4 siRNA or a scrambled siRNA or with an empty (E) plasmid, with 
wild-type (WT), longevity associated variant (LAV) BPIFB4-encoding 
plasmids. Right graphs show quantification of eNOS phosphorylation and 
BPIFB4. Values are means ± SEM, N=2 pools of experiments. Statistics 
was performed using ANOVA; **, p<0.01; ***, p<0.001 
 
 
 
1.14 LAV-BPIFB4 enhances eNOS phosphorylation and 
endothelial function 
We transfected mesenteric arteries ex vivo with plasmids encoding a 
variant tagged with green fluorescent protein (GFP). Overexpression of 
WT-BPIFB4 did not interfere with vascular reactivity (Figure 1.13B), 
whereas the expression of LAV-BPIFB4 significantly enhanced 
acetylcholine-evoked vasorelaxation and promoted phosphorylation of 
eNOS at serine 1177 (Figure 1.13C). Of note, acetylcholine-evoked 
vasorelaxation was more efficiently inhibited with NG-nitro-L-arginine methyl 
ester (L-NAME) in LAV-BPIFB4-expressing resistance vessels than in 
vessels exposed to an empty vector, indicating a higher presence of NO in 
the former94. 
We then assessed the importance of LAV-BPIFB4 phosphorylation and 14-
3-3 binding for activation of eNOS. When we transfected mouse mesenteric 
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arteries ex vivo with LAV-BPIFB4mutPERK or LAV-BPIFB4mut14-3-3, we 
encountered endothelial dysfunction associated with inhibition of eNOS 
(Figure 1.14A and 1.14B). Pharmacological inhibition of PERK with 
GSK2606414 after transfection with LAV-BPIFB4 also resulted in blunted 
eNOS phosphorylation and impairment of endothelial function (Figure 
1.14A, 1.14B and 1.14C)94. 
Phosphorylation of BPIFB4 at serine 75 was higher in mesenteric vessels 
transfected with LAV-BPIFB4 than in those transfected with WT-BPIFB4 
(Figure 1.14D). Treatment with GSK2606414 reduced the level of 
phosphorylation at serine 75 on LAV-BPIFB4, as well as at serine 1177 on 
eNOS, supporting the role of PERK in potentiating the phosphorylation 
status of LAV-BPIFB4 and eNOS (Figure 1.14C). Because mesenteric 
vessels transfected with WT-BPIFB4mut14-3-3 also displayed endothelial 
dysfunction, it is plausible that WT-BPIFB4, similarly to LAV-BPIFB4, 
requires binding to 14-3-3 for activation of eNOS94. 
Further evidence in support of a role of HSP90 in mediating LAV-BPIFB4’s 
potentiation of eNOS came from LAV-BPIFB4’s failure to modulate 
eNOS/endothelial function upon inhibition of HSP90 with SNX5422 . As a 
result, we hypothesize a model in which BPIFB4 needs to be 
phosphorylated by PERK to recruit 14-3-3, a step required to allow a 
complex to form with HSP90 and, hence, the activation of eNOS; this 
cascade of events is potentiated in the presence of LAV-BPIFB4. 
We also observed apparently paradoxical reductions in potassium- and 
phenylephrine-evoked vasoconstrictions by LAV-BPIFB4 compared with 
WT-BPIFB4. This effect was partially rescued by the eNOS inhibitor L-
NAME, suggesting that LAV-BPIFB4-mediated enhancement of NO 
production modulated adrenergic and potassium vascular responses 
(Figure 1.14B)94. 
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Figure 1.14. Effect of the NO inhibitor L-NAME, LAV-BPIFB4mutPERK, 
LAV-BPIFB4mut14-3-3, and the PERK inhibitor GSK2606414 on LAV-
BPIFB4-mediatedvascular reactivity and on phosphorylation of eNOS 
in mesenteric arteries. A, The graphs show, from left to right, the vascular 
response of ex vivo mouse mesenteric arteries to potassium (80mM KCl), 
and the dose–responses to phenylephrine (PE), to the thromboxane 
agonist U46619, and to acetylcholine (ACh), before transfection ( ), after 
transfection with LAV-BPIFB4 ( ), or after transfection with LAV-BPIFB4 
plus L-NAME (300μM) in the first row, LAV-BPIFB4mutPERK in the second 
row, LAV-BPIFB4mut14-3-3 in the third row, and LAV-BPIFB4 plus 
GSK2606414 (0.5 μM) ( ) in the last row. Values are means ± SEM. N=7 
experiments per group. Statistics was performed using ANOVA; *, p<0.05; 
**, p<0.01; ***, p<0.001 before vs after transfection or treatment. B, 
Western blot of seven pooled experiments on ex vivo mouse mesenteric 
arteries transfected with LAV-BPIFB4, LAV-BPIFB4mutPERK, LAV-
BPIFB4mut14-3-3, or LAV-BPIFB4 plus GSK2606414. Graphs show 
quantification of eNOS phosphorylation and BPIFB4. Values are means ± 
SEM, N=2 pools of experiments. Statistics was performed using ANOVA; 
**, p<0.01. C, Western blot of four pooled experiments on ex vivo mouse 
mesenteric arteries with LAV-BPIFB4 or LAV-BPIFB4 plus GSK2606414. 
Graphs show quantification of eNOS and BPIFB4 phosphorylation. D, 
Western blot of four pooled experiments on ex vivo mouse mesenteric 
arteries with WT-BPIFB4, LAV-BPIFB4 plus GSK2606414, or LAV-BPIFB4. 
Graphs show quantification of eNOS and BPIFB4 phosphorylation. LAV-
BPIFB4, mutated variant; LAV-BPIFB4mutPERK, LAV-BPIFB4 with a Ser75Ala 
variation; LAV-BPIFB4mut14-3-3, LAV-BPIFB4 with a Ser82Asn variation. N=1 
pool of experiments. 
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1.15 Forced expression of LAV-BPIFB4 in vivo 
enhances eNOS function and reduces blood pressure 
To evaluate the in vivo relevance of the findings obtained through plasmid 
transfection, we generated WT-BPIFB4-, LAV-BPIFB4- and GFP-encoding 
adeno-associated viral vectors (AAV serotype 9 with a TBG promoter) and 
used them to transduce normotensive mice through the femoral artery.98 
We found that AAV-LAV-BPIFB4 enhanced NO-mediated vasorelaxation in 
femoral and mesenteric arteries explanted after seven days; this effect was 
associated with potentiation of eNOS phosphorylation and with a reduction 
of both systolic and diastolic blood pressure. Transduction with AAV-WT-
BPIFB4 did not influence NO-mediated vasorelaxation at either the 
functional or molecular level.  
AAV-LAV-BPIFB4 localized throughout the whole vessel, enhancing eNOS 
phosphorylation.  
There were no significant quantitative differences in BPIFB4 from rats 
receiving AAV-LAV-BPIFB4 or AAV-GFP in serum (507± 92  vs 551±56 
pg/mL P=0.339) and MNCs (as measured by ELISA (Cusabio) and 
Western blot, respectively. Thus, we conclude that the effect observed was 
due to LAV-BPIFB4 expression in the whole vessel94. 
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2. AIM OF THE WORK  
 
The scope of this thesis is the disclosure of molecular mechanisms that 
regulate aging process. In particular, the mechanisms involved in BPIFB4 
pathway that we found mutated in three centenarians populations. 
A recent paper pointed out that BPIFB4 plays a crucial role in maintenance 
of vascular homeostasis and that LAV-BPIFB4 exerts extra protection. It 
shows that biomechanical stress due to increased arterial pressure up-
regulated BPIFB4 expression, and that BPIFB4 silencing induced 
eNOS/endothelial dysfunction. 
LAV-BPIFB4 potenciate eNOS and endothelial function, compared to WT-
BPIFB4 treated vessels. In agreement, LAV-BPIFB4 showed higher serine 
75 phosphorylation and improved ability to bind 14-3-3 as compared to WT 
isoform. 
In order to better clarify the mechanisms involved in LAV-BPIFB4 
potentiation of eNOS and endothelial function, here we further investigated 
additional potential players, focusing our attention on PKC-alpha, which is 
one of the major PKC expressed in endothelial cells able to regulate eNOS 
function. 
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3. MATERIALS AND METHODS 
3.1 Ex vivo transfection of mouse vessels and 
evaluation of vascular reactivity 
Second-order branches of the mesenteric arterial tree were removed from 
C57BL6 mice and transfected as described previously99. Briefly, vessels 
were placed in a Mulvany pressure system filled with Krebs solution 
supplemented with 20 μg of the pRK5 vector encoding either WT-BPIFB4, 
LAV-BPIFB4, LAV-BPIFB4mutPERK, or LAV-BPIFB4mut14-3-3, or with an empty 
plasmid as a negative control. All vessels were perfused at 100 mmHg for 1 
hr and then at 60 mmHg for 5 hrs. Endothelium-dependent relaxations was 
assessed by measuring the dilatory responses of mesenteric arteries to 
cumulative concentrations of acetylcholine (from 10−9 M to 10−5 M) in 
vessels pre-contracted with U46619 at a dose necessary to obtain a similar 
level of pre-contraction in each ring (80% of initial KCl-evoked 
contraction)79. The maximal contraction evoked by U46619 was considered 
as the baseline for subsequent evoked vasorelaxations. Acetylcholine 
vasorelaxation was tested in the presence of Gӧ6976 (0.5 μM), a PKC 
inhibitor. Another experimental series was performed in absence of external 
Ca2+ using Ca2+-free Krebs and in presence of apamin (Sigma-Aldrich), a 
potent inhibitor of ATP-type Ca+2-activated K+ channels and charybdotoxin 
(Sigma-Aldrich), a potent and selective inhibitor of the Ca2+-activated 
K+ channel and voltage-gated (Kv1.3) channel. Caution was taken to avoid 
endothelial damage; the corresponding values are reported as the 
percentage of lumen diameter change after drug administration. Responses 
were tested before and after transfection. 
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3.2 Cell culture and Co-immunoprecipitation 
Human embryonic kidney cells (HEK293T) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal 
bovine serum and 1% non-essential amino acids at 37° C in a 5% CO2 
atmosphere. For co-immunoprecipitation assay 1,4x106 cells were plated in 
10cm dish and transfected with pRK5 vector encoding LAV-BPIFB4 or with 
an empty plasmid6, using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s protocol. Twenty-four hours post-
transfection, HEK293T cells were incubated with PKC-alpha inhibitor 
Go6976 (0.3 μM) for other twenty-four hours, harvested and solubilized in 
lysis buffer (20 mMTris-HCl, pH7.5, 650 mM sodium chloride, 500 mM 
EDTA, 250 mM EGTA, and Triton X-100). The cell lysates were cleared at 
13,000 rpm for 20 min at 4ºC and 700 μg protein were incubated overnight 
with 2 μg of anti-GFP (Invitrogen, mouse mAb), anti-14-3-3 (Abcam, mouse 
mAb), and anti-IgG (Millipore, mouse pAb) for control. The antibody–
antigen complexes were precipitated with protein Glinked Sepharose (GE 
Healthcare) for 4 hr at 4°C and the beads were washed three times with 
lysis buffer. The denatured co-immunoprecipitation products were resolved 
with SDS-PAGE, electro-blotted onto PVDF membranes, and hybridized 
with anti-14-3-3 (Abcam, rabbit pAb, 1:1000). 
 
 
3.3 Western blotting 
Western blotting was performed on pooled protein extracts from transfected 
perfused vessels, or from MNCs. Protein extracts were separated on 10% 
SDS-PAGE at 100V for 1 hr or on 4–12% SDS-PAGE at 100V for 2 hrs and 
then transferred to a nitrocellulose or PVDF membrane. The membranes 
were incubated overnight with the following primary antibodies: anti-
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phospho-eNOS Ser1177 (Cell Signaling Technology, rabbit mAb, 1:1000), 
anti-eNOS (Cell Signaling Technology, mouse mAb, 1:800), anti-phospho-
BPIFB4 Ser75 (developed by Prof. Annibale Puca in collaboration with 
Areta International)100 anti-BPIFB4 (Abcam, rabbit pAb, 1:200), anti-beta-
actin (Cell Signaling Technology, mouse mAb, 1:3000), anti-PKC-alpha 
phospho-T497 (Abcam, rabbit mAb, 1:10000), anti-PKC-alpha (Abcam, 
rabbit mAb, 1:1000). After a triple wash, membranes were incubated for 1 
or 2 hrs with the secondary antibody (Amersham Life Science, horseradish 
peroxidase-linked anti-rabbit IgG or anti-mouse IgG, 1:3000). The 
membranes were then washed four times and specific protein bands were 
detected with ECL Prime chemiluminescent agents (Amersham Life 
Science). Western-blot data were analyzed using ImageJ software 
(developed by Wayne Rasband, National Institutes of Health, USA) to 
determine optical density (OD) of the bands. The OD readings of 
phosphorylated proteins were expressed as a ratio relative to total protein 
or to beta-actin. All other protein expressions were normalized to beta-actin 
to account for variations in loading. 
 
 
3.4 Ca2+-transient recordings 
HEK293 cells were grown in DMEM (Gibco) supplemented with 10% fetal 
calf serum. For transfections, 100 μl DMEM was mixed with 2 μl 
Magnetofection NeuroMag (OZ Bioscience, France) and 1 μg of the 
hBPIFB4 cDNA subtype or empty vector. The mixture was incubated for 
15–20 min at room temperature and thereafter distributed drop-wise over 
the culture. Cells were then placed on a magnetic plate (OZ Bioscience) 
and incubated for 15 min at 37°C. Cells were used for the experiments 48–
76 h after transfection. Efficacy of transfection was assessed by 
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fluorescence microscopy, monitoring the amount of cells expressing vector-
encoded GFP.  
Free intracellular Ca2+ concentration ([Ca2+]i) recordings were obtained by 
time-resolved digital fluorescence microscopy in HEK cells loaded with the 
Ca2+ indicator X-rhod-1 AM (excitation 550 nm; emission 610 nm)101 to 
avoid overlapping of fluorescence signals due to the presence of GFP. 
Briefly, cells were serum-starved for 2 h and incubated 45 min at 37°C with 
the cell-permeant X-rhod-1 AM (2 μM). Cells were then placed in standard 
mammalian Ringer’s solution (in mM: NaCl, 140; KCl, 2.5; CaCl2, 2; MgCl2, 
2; Hepes-NaOH, 10; and glucose, 10; pH 7.3), and continuously 
superfused with a gravity-driven fast-perfusion system (BioLogique 100, 
France). Most cells were transfected and displayed clear GFP fluorescence 
that did not interfere with the fluorescent signal of the Ca2+ dye X-rhod-1. 
Ca2+ transients were elicited by applying ATP 100 μM for 10 s. The time 
courses of Ca2+ transients were quantified by measuring at each time point 
the fluorescence emission in each cell, and then transforming the obtained 
values as ΔF/F = [F(t)-F(0)] / F(0). The overall ATP-induced Ca2+ 
mobilization was evaluated as Q-Ca2+6min = ΔF/Fdt, calculated 6 min from 
ATP application. All cells in the optical fields were averaged, given that a 
detailed analysis discriminating GFP-positive and -negative cells yielded no 
statistical difference between the two subsets (not shown), indicating that 
HEK293 extensive electrical coupling102 underlies the Ca2+ response. 
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3.5 Immunofluorescence and confocal microscopy 
HEK293T grown in multichamber slides were transfected with pRK5 vector 
encoding WT- or LAV-BPIFB4 or with an empty plasmid. Twenty-four hours 
post-transfection, the cells were fixed in 4% Para formaldehyde in PBS for 
20 min, washed twice in 50 mM NH4Cl in PBS, and permeabilized for 5 min 
in 0.2% Triton X-100 in PBS. Fixed cells were treated as described103. 
Immunofluorescence analysis was performed at a confocal laser-scanning 
microscope LSM 510 Meta (Zeiss, Gottingen, Germany). The λ of the two 
HeNe lasers was set at 543 and at 633 nm. Fluorescence emission was 
revealed by 560–615 band pass filter for Alexa Fluor 546, and by 615 long 
pass filter for DRAQ5. Double-staining immunofluorescence images were 
acquired separately in the red, and infrared channels at a resolution of 
1024 x 1024 pixels, with the confocal pinhole set to one Airy unit and then 
saved in TIFF format. 
 
 
3.6 Statistical analyses  
Vessel reactivity results are given as mean ± standard error of mean 
(SEM). Data were analyzed with Student’s t-test or two-way ANOVA 
followed by Bonferroni post-hoc analysis, as appropriate, using dedicated 
software (GraphPad Prism Software, version 5.0). Densitometry data were 
analyzed with Student’ s t-test or two-way ANOVA, as appropriate, using a 
dedicated software (GraphPad Prism Software, version 5.0). Unpaired 
Student’ s t-test was used to compare the mean (± SEM) of the OD of MNC 
data about the wild-type, homozygous and the heterozygous carriers of the 
rs2070325 variation.  
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4. RESULTS 
4.1 LAV-BPIFB4 activates PKC-alpha. 
We previously reported that LAV-BPIFB4 enhanced acetylcholine evoked 
nitric oxide vasorelaxation94. Acetylcholine-evoked vasodilation of isolated 
mesenteric vessels has been reported to require an intact PKC-alpha 
activity104. Here, we found that PKC-alpha was more phosphorylated (at 
threonine 497, an activation site of the enzyme) in LAV-BPIFB4-expressing 
vessels than in those treated with an empty or WT-vector (Figure 1A).  
Treatment with the PKC-alpha inhibitor Gö6976 significantly blunted the 
acetylcholine-induced vasorelaxation in control vessels (Figure 2A) and 
abolished both enhanced eNOS phosphorylation and endothelial 
vasorelaxation of LAV-BPIFB4-expressing vessels (Figure 2B-C) Based on 
these results we can assert that PKC-alpha is recruited by LAV-BPIFB4 to 
modulate eNOS and vascular tone. 
 
 
4.2 BPIFB4 isoforms modulate Ca2+ and PKC-alpha 
membrane translocation 
Based on the modulatory actions of BPIFB4 on vascular function and on 
PKC-alpha activity, which are well-known Ca2+-dependent processes,104 we 
investigated how agonist-induced Ca2+ mobilization was influenced by the 
expression of these proteins. Thus, we studied the ATP-induced Ca2+ 
transients in HEK293T cells transfected with different BPIFB4 isoforms.  
The expression of WT-BPIFB4 promoted a slight increase in Ca2+ influx, 
with an enhancement of the mean Ca2+ mobilization and a higher number 
of responding cells to ATP stimuli compared to empty vector (Figure 3A-B-
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C). The expression of LAV-BPIFB4 further and strongly enhanced the 
percentage of responding cells and Ca2+ mobilization (Figure 3A-B-C), 
indicating a facilitation of agonist-induced Ca2+ release. Fluorescence 
analyses of HEK293T cells revealed that only after LAV-BPIFB4 
transfection there is an increase of PKC-alpha localized to the plasma 
membrane -a known hallmark of activated PKC-alpha105- compared to 
empty or WT-BPIFB4 transfected cells (Figure 3D). PKC-alpha activation 
occurs in all cells, despite only a fraction of them were efficiently 
transfected with LAV-BPIFB4, further supporting a role of Ca2+ that is 
known to be able to propagate among cells through tight junctions.106  
Taken together, these data clearly suggest that LAV-BPIFB4 is able to 
enhance Ca2+ influx leading to PKC-alpha activation.   
 
 
4.3 LAV-BPIFB4 fails to modulate PKC-alpha and eNOS 
in absence of external Ca2+  
Acetylcholine induced eNOS phosphorylation requires Ca2+ influx.104 To 
clarify the role of Ca2+ in LAV-BPIFB4 vascular action we performed 
vascular reactivity studies in mesenteric arteries in absence of external 
Ca2+. In external Ca2+-free condition, LAV-BPIFB4 was hypo-
phosphorylated and not able to enhance PKC-alpha and eNOS 
phosphorylation (Figure 4A). In this experimental setting, LAV-BPIFB4 was 
still able to enhance endothelial vasorelaxation (Figure 4B). It is well know 
that in addition to NO, endothelium generates other mediators involved in 
the regulation of vascular tone and among these endothelium-derived 
hyperpolarizing factors (EDHF) plays a prominent role.107 Thus, we aimed 
to inhibit EDHF release using apamin plus charybdotoxin. In particular, we 
showed that during the inhibition of EDHF release, in absence of external 
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Ca2+, acetylcholine evoked vasorelaxation was abolished and LAV-BPIFB4 
failed to enhance endothelial vasorelaxation (Figure 4C). Taken together 
our data demonstrate that external Ca2+ mobilization is necessary to LAV-
BPIFB4 to activate PKC-alpha and eNOS signalling, while in its absence 
LAV-BPIFB4 up-regulate additive mechanisms (EDHF) to enhance 
endothelial function. 
Our conclusion is supported by experiments performed in eNOS knockout 
murine vessels that demonstrated that LAV-BPIFB4, in absence of eNOS 
signalling, was still able to enhance endothelial vasorelaxation, again 
blunted by apamin plus charybdotoxin (Figure 4D).    
 
 
4.4 Feed-forward mechanism of PKC-alpha vascular 
action  
We have previously showed that BPIFB4 phosphorylation by stress kinase 
PERK at serine 75 induced its binding to 14-3-3. The phosphorylation at 
serine 75 and the 14-3-3 binding was higher in LAV-BPIFB4 than in WT-
BPIFB4 and its phosphorylation and 14-3-3 binding status correlated with 
its ability to activate eNOS and endothelial function94 As further support of 
the role of phospho-BPIFB4 and BPIFB4-14-3-3 binding in eNOS 
activation, mutagenesis of the serine 75 (LAV-BPIFB4mutPERK) and the 
serine in the 14-3-3 binding site (LAV-BPIFB4mut14-3-3) or pharmacological 
treatment with GSK2606414, a PERK inhibitor, showed a blunted eNOS 
phosphorylation at Ser1177 (Figure 5A) and reduced acetylcholine 
endothelial vasorelaxation associated with a loss of 14-3-3 
immunoprecipitation94. Overall, these data indicate that BPIFB4 is crucial 
for eNOS activation, which is activated by phosphorylation of BPIFB4 at 
serine 75 and 14-3-3 binding.  
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A detailed amino acid sequence analysis showed that serine 75 of BPIFB4 
is also a potential phosphorylation substrate motif for PKC-alpha (amino 
acids 73-75: SXR/SIR).  
Thus, we hypothesized that PKC-alpha contributes to eNOS activation also 
through BPIFB4 phosphorylation. Here, we demonstrate that treatment with 
the PKC-alpha inhibitor Gö6976 significantly reduced LAV-BPIFB4 
phosphorylation at serine 75 and eNOS phosphorylation as compared to 
vessels treated with LAV-BPIFB4 alone (Figure 2C), indicating that PKC 
alpha activation is needed for LAV-BPIFB4 phosphorylation and eNOS 
activation. Finally, in presence of PKC-alpha inhibitor, LAV-BPIFB4 lost its 
ability to co-immunoprecipitate 14-3-3 in vitro, as a consequence of its 
hypo-phosphorylation (Figure 5B), further supporting the role of PKC-alpha 
in modulating serine 75 phosphorylation and the dependent 14-4-3 binding. 
To further characterize PKC-alpha/LAV-BPIFB4 interaction, we evaluated 
PKC-alpha phosphorylation in mesenteric vessels transfected with LAV-
BPIFB4mutPERK, LAV-BPIFB4mut14-3-3, or with LAV-BPIFB4 plus GSK2606414. 
Surprisingly, in this experimental setting, while eNOS phosphorylation was 
diminished, PKC-alpha signaling was still activated (Figure 5A).  
Overall, these data, together with the described LAV-BPIFB4 activation of 
Ca2+ and PKC-alpha, with the latter inhibited in Ca2+-free conditions, 
suggest that LAV-BPIFB4, enhancing Ca2+ influx, leads to PKC-alpha 
activation through alternative mechanisms that do not require serine 75 
phosphorylation.  
Thus, we envision a model in which Ca2+/PKC-alpha (and PERK) allow 
hyper-phosphorylation of LAV-BPIFB4, increase of its binding to 14-3-3, 
HSP90 (as previously demonstrated)94 and eNOS interaction enhancing its 
phosphorylation by PKC-alpha.  
 
 
 46 
4.5 PKC-alpha is phosphorylated in MNC of LLIs 
Our data obtained in experimental models candidate PKC-alpha as a 
crucial signalling molecule recruited by LAV-BPIFB4 to enhance endothelial 
nitric oxide release. Interestingly, mononuclear cells from homozygous-
rs2070325 individuals had significantly increased phosphorylation of PKC-
alpha at threonine 497 (Figure 6A-B), thus confirming the signalling 
recruited by LAV-BPIFB4, identified in experimental models, also in human 
cells. 
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5. DISCUSSION 
BPIFB4 belongs to the superfamily of bactericidal BPI/PLUNC proteins, 
which are central to the host innate immune response against bacteria in 
regions of significant bacterial exposure, like the mouth, nose and lungs. 
The expression of the activity-enhanced polymorphic variant LAV-BPIFB4 
might initially produce privileged survival through better resistance to 
infectious diseases. The variant may offer additional advantages because 
of its ability to activate the nitric oxide (NO)-releasing enzyme eNOS. NO 
and peroxynitrite, which is generated by the interaction of NO with O2− 
during the respiratory burst, are mediators of the bactericidal effects of 
macrophages through inactivation of heme-containing enzymes, including 
cytochrome oxidases and cytochrome P450. Interestingly, development 
and refining of this prosurvival mechanism has facilitated exceptional 
longevity by ensuring better adaptation to stress conditions through 
improved function of ribosomal biogenesis, protein synthesis and 
cardiovascular homeostasis94. 
Endothelial dysfunction is a systemic pathological state characterized by a 
reduction in the bioavailability of and/or responsiveness to vasodilators, and 
altered vascular wall metabolism. It is well known that cardiovascular risk is 
markedly increased in aged individuals. Because of its major causal role in 
cardiovascular diseases, such as hypertension and ischemia, therapeutic 
agents that restore endothelial function are of clinical interest, expecially in 
the context of aging. In this context, a body of evidence pinpoints eNOS as 
a major player in blood pressure homeostasis and eNOS downregulation 
as a hallmark of cardiovascular disease108. A recent study evaluated the 
effect of LAV-BPIFB4 in a rat model of essential hypertension characterized 
by impaired endothelial function94. The in vivo administration of LAV-
BPIFB4 normalized blood pressure levels and endothelial function in 
genetically hypertensive rats, without influencing vascular remodeling.  
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The same study showed the association of dysfunctional endothelial-
dependent vasorelaxation, reduced eNOS phosphorylation and BPIFB4 
downregulation in old mice. Importantly, it demonstrated that forced 
BPIFB4 expression by LAV-BPIFB4 restores endothelium-dependent 
vasorelaxation, eNOS phosphorylation and reduces blood pressure levels 
in old mice94. 
The main finding of my thesis is that LAV-BPIFB4 is able to enhance NO 
production trough PKC-alpha signaling activation. In HEK293 cells, LAV-
BPIFB4 per se evokes Ca2+ mobilization and PKC-alpha translocation on 
plasma membrane, a step necessary for its activation105. The removal of 
external Ca2+ from vessels abolishes the ability of LAV-BPIFB4 to enhance 
both PKC-alpha and eNOS phosphorylation, although it is still able to 
enhance endothelial vasorelaxation which depends on its action on EDHF 
signaling.  
Mammalian PKC-alpha consists of 672 amino acids and is distributed in all 
tissues, in contrast to other PKC proteins whose expression is restricted in 
the particular cell types. PKC-alpha is activated by a variety of signals, 
including signals binding to guanine-nucleotide-binding protein-coupled 
receptors and to tyrosine kinase receptors, and also physical stresses like 
hypoxia and mechanical strain. 
Diacylglycerol (DG) and Ca2+ increased in the cell upon stimulation 
synergistically drive the release of a pseudosubstrate region from the active 
site, leading to activation. Also, activity of PKC-alpha is regulated by 
phosphorylation of three conserved residues in its kinase domain: the 
activation-loop site Thr-497, the autophosphorylation site Thr-638, and the 
hydrophobic C-terminal site Ser-657. PKC-alpha exhibits almost no activity 
without phosphorylation at these sites. After stimulation, PKC-alpha moves 
from cytosol to a so-called particulate fraction. This movement was first 
identified by western blotting using a specific antibody against PKC-alpha 
after fractionation of cells and later by immunofluorescent study. Recently, 
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new approaches to analyze the localization of the protein in cells, such as 
fluorescence resonance energy transfer (FRET) and confocal microscopy, 
provide a tool for identifying the exact location of PKC-alpha. 
Stimulation with phorbol myristate acetate (PMA), a non-specific activator o 
f PKCs, cause the traslocation of PKC-alphato the membrane of the cell 
where DG is produced109. 
There are at least 10 distinct lipid-regulated isoforms of PKC that can be 
divided into three categories: conventional Ca2+-dependent (cPKCs), novel 
Ca2+-independent (nPKCs), and atypical Ca2+- and diacylglycerol/phorbol 
ester-independent (aPKCs). A comparison of the amino acid sequence of 
these isoforms points out that the Ca2+-dependent cPKCs contain a 
conserved C2 domain that is absent in the Ca2+-independent nPKCs and 
aPKCs. Therefore, it is generally thought that the C2 domain plays 
a critical role in the Ca2+-dependent activation of cPKCs110.  
Calcium is a ubiquitous second messenger in eukaryotic cells and it’s the 
regulator of a wide variety of signaling pathways such as fertilization, gene 
transcription, cell division, differentiation, muscle contraction, neuronal 
signaling, inflammation, and programmed cell death111, 112. 
Especially, intracellular Ca2+ is an important second messenger in 
endothelial cells. It acts to link external stimuli with the synthesis and 
release of the regulatory factors in endothelial cells. However, excessive 
intracellular Ca2+ in endothelial cells is detrimental. Because [Ca2+]i plays a 
dual role as the cause of both physiological and pathological events, fine 
control of [Ca2+]i in endothelial cells is obligatory113.  
The endothelium is the thin inner layer (tunica intima) of a blood vessel 
regulates the vascular tone by releasing relaxing factors in response to 
both mechanical stimuli (shear stress and cyclic strain) and soluble 
agonists (bradykinin and acetylcholine (ACh)114. It has been established 
that the calcium influx through the plasma membrane is one of the proximal 
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signaling factors in the production of relaxing factors such as nitric oxide 
(NO) and prostaglandins in response to external stimuli115. 
The endothelial cells provide a pathway for oxygen distribution from the 
blood to the tissue and also regulate the permeation of various metabolites, 
macromolecules and autocrine and paracrine factors. In addition, the 
endothelium has its own functions. To this end, endothelial cells produce 
many unique molecules, including NO, plasminogen activator inhibitor, 
adhesion molecules, growth factors and monocyte chemoattractant protein. 
It is known that endothelial cells secret endothelium-derived relaxing factor 
(EDRF), EDHF and prostacyclin in response to hormones, chemical signals 
or mechanical stimuli. The release of EDRF was first discovered by 
Furchgott in 1980116, who found that endothelial cells produced EDRF in 
response to acetylcholine (ACh) stimulation117. In 1987, Moncada et al.118 
and Ignarro et al.119 suggested that the EDRF was NO. Nitric oxide 
circulates from the endothelial cells to the underlying smooth muscle cells 
and causes vascular relaxation, which, in turn, modulates blood pressure 
and blood flow113.  
The [Ca2+]i is the link between external stimuli to the synthesis and release 
of regulatory factors by endothelial cells. Changes in [Ca2+]i modulate the 
releasing of dilators agents from endothelial cell . For example, an increase 
in [Ca2+]i activates endothelial NO synthase (eNOS) to generate NO. Nitric 
oxide then activates guanylyl cyclases (GCs) to produce cGMP, which itself 
or via PKG modulates the activity of Ca2+ channels and pumps in a 
feedback manner114. A rise in [Ca2+]i also stimulates EDHF release and this 
release may be partly attributed to the fact that increases in [Ca2+]i activate 
the small- and intermediate-conductance Ca2+-sensitive K+ channels in 
endothelial cells. 
In our recent paper we have demonstrated that LAV-BPIFB4 potentiated 
eNOS and endothelial function as compared to WT-BPIFB4 treated vessels 
and that serine 75 phosphorylation of BPIFB4 by PERK is fundamental for 
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eNOS activation and endothelial function.100 In agreement, LAV-BPIFB4 
showed higher serine 75 phosphorylation and improved ability to bind 14-3-
3 as compared to WT isoform94.  
In order to better clarify the mechanisms involved in LAV-BPIFB4 
potentiation of eNOS and endothelial function, here we further investigated 
additional potential players, focusing our attention on PKC-alpha, which is 
one of the major PKC expressed in endothelial cells able to regulate eNOS 
function.115, 120  
PKC-alpha stimulates NO production in endothelial cells by increasing 
phosphorylation of Ser1179 while having no effects on Thr497 of eNOS. 
Pretreatment of bovine aortic endothelial (BAEC) cells with Gö6976, an 
inhibitor of calcium-dependent PKC inhibits FGF-2 induced eNOS- Ser1179 
phosphorylation115.  
Here we showed that PKC-alpha inhibitor Gö6976 impeded LAV-BPIFB4 
potentiation of eNOS and endothelial function, thus positioning PKC-alpha 
between LAV-BPIFB4 and eNOS. To be noted, transfection of vessels with 
LAV-BPIFB4mutPERK, and with LAV-BPIFB4mut14-3-3, or with LAV-BPIFB4 plus 
PERK inhibitor didn’t interfere with LAV-BPIFB4 ability to potentiate PKC-
alpha although blunted eNOS activation. These data indicate that PKC-
alpha activation is not dependent on LAV-BPIFB4 phosphorylation and 
binding to 14-3-3. 
In our experiments in vitro, we showed that WT- and LAV-BPIFB4 both 
improved mobilization of Ca2+, with the latter being more efficient than the 
former. This effect of LAV-BPIFB4 is associated with higher amount of 
PKC-alpha translocation on plasma membrane and the data obtained in 
vessels, in external Ca2+-free condition, clearly demonstrate that external 
Ca2+ is crucial for the mechanisms recruited by LAV-BPIFB4 to enhance 
eNOS signaling, including PKC-alpha activation.  
To be noted, serine 75 of BPIFB4, which is a phosphorylation motif for 
PKC121 (amino acids 73-75: SXR/SIR) is hypo-phosphorylated by PKC-
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alpha inhibitor, indicating that PKC-alpha is also upstream of BPIFB4, as 
also shown by the loss of LAV-BPIFB4 ability to immunoprecipitate 14-3-3, 
which is dependent on serine 75 phosphorylation, after PKC-alpha 
inhibition in vitro.  
Overall, these data suggest that of LAV-BPIFB4, modulating Ca2+ influx, 
leads to PKC-alpha activation that in-turn increases phosphorylation in 
serine 75 of BPIFB4. The consequence of this hyper-phosphorylation 
results in the improvement of LAV-BPIFB4 binding to 14-3-3 and HSP90100 
that can interacts with eNOS, thus enhancing its phosphorylation by PKC-
alpha (Figure 7).  
However, a careful analysis of our data show that in presence of LAV-
BPIFB4 and absence of external Ca2+ in vessels, although PKC-alpha and 
eNOS phosphorylation are blunted, there was still enhancement of 
endothelial vasorelaxation. It is well known that during eNOS dysfunction, 
EDHF substitutes for nitric oxide122, 123. In agreement, we demonstrated the 
enhancement of endothelial vascular effect of LAV-BPIFB4 under the 
above conditions is mediated by a recruitment of EDHF.  
To definitively clarify the concept that LAV-BPIFB4 is able to recruit 
alternative mechanisms to protect endothelial function in absence of eNOS, 
we performed experiments in eNOS deficient mice. Also in this 
experimental model we showed an EDHF-release dependent LAV-BPIFB4 
enhancement of endothelial vasorelaxation. More studies needed to clarify 
the mechanism involved in LAV-BPIFB4 action on EDHF release, an 
experimental condition present only in absence of eNOS signaling (Figure 
7).  
Our data highlight Ca2+ mobilization and PKC-alpha activation as key 
signals necessary for LAV-BPIFB4 to enhance endothelial NO release. To 
be noted, LAV-BPIFB4 activation of PKC-alpha was shown also in 
HEK293T cells and in humans MNCs with a a/a homozygous genotype for 
rs2070325 (LAV).  
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These data corroborate the observation made on vessels and indicate a 
more broader role of LAV-BPIFB4 in modulating other functions where 
PKC-alpha is involved, such as control of stem cell maintenance, 
development, differentiation, functions that are lost during ageing and that 
could be preserved in long-living individuals.124,125 Our further 
characterization of the molecular determinants of LAV-BPIFB4 protective 
effects puts the foundation to investigate on it’s a possible translation in 
clinical field. 
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Figure 1.  Western blot of 7 pooled experiments on ex vivo C57BL/6 
mouse mesenteric arteries transfected with Empty vector (E), Wild-type 
BPIFB4 (WT), LAV-BPIFB4 (LAV) vectors. Right graphs show 
quantification of p-eNOS (S1177), p-PKC-alpha (T497) and BPIFB4. 
Values are means±SEM, n =3 pools of experiments. Statistics was 
performed using ANOVA; *p<0.05.  
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Figure 2. A, Dose–response curve to acetylcholine in ex vivo C57BL/6 
mouse mesenteric arteries transfected with empty vector (E) either 
untreated or treated with the PKC-alpha inhibitor Gö6976; B, Dose–
response curve to acetylcholine in ex vivo C57BL/6 mouse mesenteric 
arteries transfected with Empty vector (E), or with LAV-BPIFB4 (LAV) 
untreated or treated with the PKC-alpha inhibitor Gö6976. Values are 
means±SEM. n =5 experiments per group. Statistics was performed using 
ANOVA; ** p<0.01.C, Western blot of seven pooled experiments on ex vivo 
mouse mesenteric arteries from control mice, transfected with Empty 
vector, with LAV-BPIFB4 or with LAV-BPIFB4 plus PKC-alpha inhibitor 
(Gö6976). Right graphs show quantification of p-eNOS (S1177), eNOS, p-
PKC-alpha (T497), PKC-alpha, p-BPIFB4 (S75), BPIFB4 and Actin. Values 
are means ± SEM, n=3 experiments. Statistics was performed using 
ANOVA; * p<0.05 
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Figure 3. A, top, Digital fluorescence images of the same HEK293T cells 
showing expression of GFP after transient transfection with control GFP-
encoding vector (left, 480 nm excitation, 510 nm emission), X-rhod-1 
fluorescence in basal [Ca2+]i conditions (middle, 550 nm excitation, 610 nm 
emission), and at [Ca2+]i peak (right). Bottom, time-courses of [Ca2+]i 
changes elicited by 100 μM ATP (arrows, 2-second application), in 
individual HEK293T cells transiently transfected with empty vector (Empty), 
WT, LAV isoforms as indicated, in the presence of 2 mM external Ca2+. B, 
Histogram representing the percentage of cells responding with a 
detectable Ca2+ transient to ATP application. Values are averaged from 
empty, WT- and LAV-transfected cells in the presence of 2 mM external 
Ca2+(n=454, 589, 530, and 474, respectively). Statistics was performed with 
χ2 test; *, p< 0.05; ***, p< 0.001. C, Histogram of Q-Ca2+6min values (i.e. 
ΔF/F time integral, see methods), representing Ca2+ mobilization in the first 
6 min after ATP application. Values are averaged from empty, WT- and 
LAV-transfected cells in the presence of external Ca2+. Statistics was 
performed using ANOVA; ***, P < 0.001; #, p< 0.05. D, Subcellular 
localization of PKC-alpha in transfected HEK293T cells. PKC-alpha (red) 
was mainly cytosolic in HEK293T cells transfected with an empty vector 
(Empty, green); with a plasmid encoding wild-type-BPIFB4 (WT, green); in 
 57 
contrast, PKC-alpha was located mainly on the plasma membrane in 
HEK293T cells forced to express LAV-BPIFB4 variant (LAV, green), which 
is a clear hallmark of PKC-alpha activation. Nuclei (blue) were stained with 
DRAQ5. 
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Figure 4. A, Western blot of 7 pooled experiments on ex vivo C57BL/6 
mouse mesenteric arteries transfected with LAV-BPIFB4 in presence of 
Ca2+ (LAV); with empty vector in absence of external Ca2+ (E - Ca2+) or with 
LAV-BPIFB4 in absence of external Ca2+ (LAV - Ca2+). Values are means ± 
SEM, n=3 experiments. Statistics was performed using ANOVA; *, p<0.05. 
B, Dose–response curve to acetylcholine in ex vivo C57BL/6 mouse 
mesenteric arteries transfected with Empty vector (E) or with LAV-BPIFB4 
(LAV) in absence of external Ca2+ (-[Ca2+]ext). Values are means ± SEM, 
n=3 experiments. Statistics was performed using ANOVA; *, p<0.05; **, 
p<0.01. C, Dose–response curve to acetylcholine in ex vivo C57BL/6 wild-
type mouse mesenteric arteries (WT) in absence of external Ca2+ before 
(basal condition) and after transfection with LAV-BPIFB4 (LAV) or LAV-
BPIFB4 plus apamin and charybdotoxin. Values are means ± SEM, n=4 
experiments. Statistics was performed using ANOVA *, p<0.05; **, p<0.01 
after LAV + apamin + charybdotoxin; #, p<0.05; ##, p<0.01 vs. after LAV + 
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apamin + charybdotoxin; §, p<0.05; §§, p<0.01 vs. before. D, Dose–
response curve to acetylcholine in ex vivo mesenteric arteries from eNOS 
knockout mouse (eNOS KO) in absence of external Ca2+ before and after 
transfection with LAV-BPIFB4 (LAV) or LAV-BPIFB4 plus apamin and 
charybdotoxin. Values are means ± SEM, n=4 experiments. Statistics was 
performed using ANOVA; *, p<0.05; **, p<0.01 vs. before; #, p<0.05; ##, 
p<0.01 vs. after LAV + apamin + charybdotoxin; §, p<0.05; §§, p<0.01 vs. 
after LAV + apamin + charybdotoxin. 
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Figure 5. A, Western blot of 7 pooled experiments on ex vivo mouse 
mesenteric arteries transfected with LAV-BPIFB4, LAV-BPIFB4mutPERK 
(Ser75Ala variation), LAV-BPIFB4mut14-3-3 (Ser82Asn variation) or LAV-
BPIFB4 plus GSK2606414 (PERK inhibitor). Right graphs show 
quantification of p-eNOS (S1177), p-PKC-alpha (T497), and BPIFB4. 
Values are means ± SEM, n=3 experiments. Statistics was performed using 
ANOVA; ***, p<0.001. B, Co-immunoprecipitation of BPIFB4 with 14-3-3 in 
extracts of HEK293T cells overexpressing LAV-BPIFB4 tagged with GFP 
protein and treated with PKC-alpha inhibitor Gö6976. Immunoprecipitation 
was performed with anti-GFP (directed toward LAV-BPIFB4-GFP), anti-14-
3-3 and anti-IgG (as negative control) antibody followed by immunoblotting 
with anti-14-3-3. 
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Figure 6. A, Evaluation of PKC-alpha activation in subjects carrying 
mutations on BPIFB4.a, Phosphorylation at threonine 497 of PKC-alpha in 
ex vivo mononuclear cells (MNC) of subjects A/A (n=9), A/a (n=9), or a/a 
(n=9) for rs2070325. The plots on the right show the OD ratios between 
phosphorylated PKC-alpha and beta-actin. B, Plot of the average values. 
Statistics was performed with Student’s t-test comparing homozygous 
carriers; *, p< 0.05. 
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Figure 7. Representative mechanisms recruited by LAV-BPIFB4 to 
modulate eNOS. LAV-BPIFB4, modulating Ca2+ influx, leads to PKC-alpha 
activation that in-turn increases phosphorylation in serine 75 of BPIFB4. 
The consequence of this hyper-phosphorylation results in the improvement 
of LAV-BPIFB4 binding to 14-3-3 and HSP90 that can interacts with eNOS, 
thus enhancing its phosphorylation by PKC-alpha. Alternatively, in external 
Ca2+-free condition or in absence of eNOS enzyme LAV-BPIFB4 is able to 
stimulate EDHF signaling. BPIFB4 val-229 = LAV-BPIFB4; PKCα = Protein 
kinase C-alpha; HSP90 = heat shock protein 90; eNOS = endothelial nitric 
oxide synthase; NO = nitric oxide; EDHF = Endothelium-derived 
hyperpolarizing factors; Ca2+ = Calcium ion. 
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6. WORK IN PROGRESS AND FUTURE 
PERSPECTIVES 
 
  
The way toward pharmacology of aging still follows the perception of the 
discovery of a mimetic drug for dietary restriction (DR), which is the only 
recognized efficient way to delay aging.  
Indeed, none of the alternative anti-aging therapies has been tested in 
humans, except for caloric restriction. To be noted, we, as others, are 
interested in health-span more than lifespan, and to this end, it’s important 
to understand when it’s better to start a treatment that could reduce or 
delay the effects of ageing on a particular body district.  
The results reported in our recent work, which has been summarized in this 
thesis, about the impact on endothelial vasorelaxation of the administration 
of Adeno-Associated Viral vectors carrying the LAV isoform of BPIFB4 in 
mouse models, encouraged us to start clinical trials. Viral mediated gene 
therapy could represent a realistic and nearby achievement and maybe it’s 
suitable for a longer and more performing solution of age-related diseases.  
The benefits of using AAV for gene therapy include long-term gene 
expression, the inability to autonomously replicate without a helper virus, 
transduction of dividing and nondividing cells, and the lack of pathogenicity 
from wild-type infections. 
On the other hand, alternative roads of administration, such as recombinant 
protein administered orally or intravenous, are better from a 
pharmacological and industrial prospective but it requires an enormous 
technical and economic support. 
We are going to set up the preliminary characterization of the recombinant 
protein, expressing LAV-BPIFB4 in mammalian cells as they are the best 
host for the expression of recombinant vertebrate proteins because they 
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produce the same posttranslational modifications and recognize the same 
signals for synthesis, processing, and secretion utilized in the organism 
from which the sequence was originally derived. Once expressed, the 
recombinant protein will be purified using Ni-NTA affinity chromatography 
under native conditions and will be eluted. The quality and purity of LAV-
BPIFB4 recombinant protein will be checked. 
Human administration must be preceded by the pre-clinical evaluation of 
the AAV vector and recombinant protein including toxicology, safety, 
minimal dose administrable, and bio-distribution of the serotype, and these 
are very long and expensive steps. 
Based on the data obtained in my thesis that suggest a more broader role 
of LAV-BPIFB4 in modulating other functions where PKC-alpha is involved, 
such as control of stem cell maintenance, development, differentiation, 
functions that are lost during ageing and that could be preserved in long-
living individuals, we envision oa broad anti-aging application for LAV-
BPIFB4.124,125  
Indeed, BPIFB4 is a multitasking protein involved in processes that are 
important for cellular functions, whose role in modulating eNOS is 
potentiated by the variations harbored by the LAV isoform. 
The additional action of LAV-BPIFB4 on EDHF release open new scenarios 
for still unexplored therapeutic targets that could benefit by the alternative 
mechanisms other than eNOS for activating endothelial function. 
Briefly, our further characterization of the molecular determinants of LAV-
BPIFB4 protective effects puts the foundation to investigate on it’s a 
possible translation in clinical field. 
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